Trial Profile
A phase IV study, prospective, randomised, open label, blinded endpoint, parallel group, 9 weeks of comparison between oral administration of telmisartan tablet (80mg once daily) and amlodipine tablet (10 mg once daily) on biological PPAR gamma [peroxisome proliferator-activated receptor gamma] activities in non controlled hypertensive male patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary) ; Amlodipine
- Indications Hypertension
- Focus Pharmacodynamics
- Sponsors Boehringer Ingelheim
- 01 Feb 2008 Status changed from recruiting to completed.
- 01 Feb 2008 The completion date for this trial is now 1 Jan 2008.
- 14 Nov 2005 New trial record.